Arkolith/Insider Trading/SKYE/Form 4

Arsenault Kaitlyn

Chief Financial OfficerSkye Bioscience, Inc. (SKYE) · full profile →Form 4 · filed Nov 6, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 6, 2023Grant(A)128K—$0186K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 6, 2023Grant(A)32K—$045K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001516551-23-000096) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML